Sungkyunkwan University · Medicine
Professor Jeong-Won Lee's research lab focuses on identifying novel molecular targets and therapeutic strategies for aggressive gynecological cancers, particularly cervical and epithelial ovarian cancer (EOC). The lab investigates the roles of non-coding RNAs, such as miRNAs, and key signaling molecules like sphingosine kinase 1 (SK1) and autophagy regulators in tumor progression and drug resistance. Using preclinical models, including patient-derived cell lines and orthotopic xenografts, the lab evaluates targeted therapies, antibody-drug conjugates (e.g., 1C1-mcMMAF), and combination regimens (e.g., chloroquine with cisplatin) to overcome chemoresistance and improve treatment outcomes. The overarching goal is to translate molecular insights into effective prognostic biomarkers and precision therapies for gynecologic malignancies.
Figures are computed from collected data and may differ slightly.
Our results show that miRNA deregulation may play an important role in the malignant transformation of cervical squamous cells. In addition, they may offer new candidate targets to be exploited for both prognostic and therapeutic strategies in patients with cervical cancer.
The 1C1-mcMMAF immunoconjugate had antitumor activity in preclinical models of ovarian carcinoma.
Overcoming drug-resistance is a big challenge to improve the survival of patients with epithelial ovarian cancer (EOC). In this study, we investigated the effect of chloroquine (CQ) and its combination with cisplatin (CDDP) in drug-resistant EOC cells. We used the three EOC cell lines CDDP-resistant A2780-CP20, RMG-1 cells, and CDDP-sensitive A2780 cells. The CQ-CDDP combination significantly decreased cell proliferation and increased apoptosis in all cell lines. The combination induced expressi
Sphingosine kinase 1 (SK1) is over-expressed in multiple types of human cancer. SK1 has growth-promoting effects and has been proposed as a potential therapeutic target. We investigated the therapeutic effects of SK1 inhibition in epithelial ovarian carcinoma (EOC). SK1 siRNA or inhibitors were tested in EOC cell lines, including A2780, SKOV3ip1, A2780-CP20, SKOV3-TR, ES2 and RMG2. Cells were treated with SK inhibitor or FTY720, and cell proliferation, apoptosis, angiogenesis and invasion were e
Open papers in the app to read, cite, and organize with AI.
